Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune’s Chief Medical Officer, Dr. Scott Harris, noted the potential of GLP-1 agents like pemvidutide to reduce alcohol cravings, referencing preclinical studies showing significant ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first ...

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $22.17, implying a 284.90% upside from current levels. In a report released yesterday, Piper Sandler also ...

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab ...

Altimmune Inc. (ALT) reported its first-quarter 2025 financial results, revealing a narrower-than-expected loss. The company’s reported earnings per share (EPS) were -$0.26, surpassing analyst ...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Altimmune ALT will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Altimmune to report an ...

Shares of Altimmune, Inc. (ALT) have gained 39.4% over the past four weeks to close the last trading session at $5.80, but there could still be a solid upside left in the stock if short-term price ...